Quantum-Si (NASDAQ:QSI) Releases Earnings Results, Beats Expectations By $0.02 EPS

Quantum-Si (NASDAQ:QSI) issued its earnings results on Thursday. The company reported ($0.10) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.12) by $0.02, FiscalAI reports. The company had revenue of $0.26 million for the quarter, compared to analysts’ expectations of $0.30 million. Quantum-Si had a negative net margin of 5,605.88% and a negative return on equity of 46.05%.

Here are the key takeaways from Quantum-Si’s conference call:

• Proteus reached a major technical milestone — Quantum-Si completed sequencing on fully integrated Proteus instruments detecting 17 amino acids and expects 18 by end-2026 with detection of all 20 during 2026 and a full sequencing kit in 2027, which management frames as a significant de‑risking versus Platinum.
• Early customer evaluations and commercial preparation look constructive — a prototype customer reported ~2x average read length and more amino acids detected versus Platinum, the company is running Proteus Roadshows and plans broader sample evaluations to build a buyer funnel, and has positioned Proteus at $425,000 versus >$1M for comparable high-end mass spec alternatives.
• Financial position supports the plan — Quantum‑Si had $190.4M in cash and investments at 3/31/26 and guides 2026 adjusted OpEx ≤ $98M and cash use ≤ $93M, projecting runway into Q2 2028 to fund Proteus completion and launch readiness.
• Near‑term revenue will remain limited — Q1 revenue was only $258k and the company reiterates 2026 revenue around ≈ $1M, describing 2026 as a transition year with modest capital sales as customers delay purchases pending Proteus availability.

Quantum-Si Stock Performance

QSI traded down $0.07 on Friday, reaching $0.91. The company had a trading volume of 13,112,028 shares, compared to its average volume of 6,228,345. Quantum-Si has a fifty-two week low of $0.69 and a fifty-two week high of $3.10. The stock has a market cap of $196.16 million, a P/E ratio of -1.78 and a beta of 3.15. The company’s fifty day moving average is $0.90 and its 200 day moving average is $1.20.

Analyst Ratings Changes

QSI has been the topic of a number of research analyst reports. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Quantum-Si in a report on Friday, March 27th. Canaccord Genuity Group dropped their target price on shares of Quantum-Si from $1.50 to $1.00 and set a “hold” rating on the stock in a report on Wednesday, March 4th. Two equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of “Hold” and a consensus price target of $3.25.

Insider Activity at Quantum-Si

In related news, CEO Jeffrey Alan Hawkins sold 83,712 shares of the company’s stock in a transaction dated Monday, April 20th. The shares were sold at an average price of $1.01, for a total value of $84,549.12. Following the transaction, the chief executive officer owned 3,776,135 shares in the company, valued at approximately $3,813,896.35. This represents a 2.17% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Charles R. Kummeth purchased 500,000 shares of the firm’s stock in a transaction that occurred on Thursday, March 5th. The stock was bought at an average price of $0.92 per share, for a total transaction of $460,000.00. Following the purchase, the director owned 855,000 shares in the company, valued at $786,600. The trade was a 140.85% increase in their position. The SEC filing for this purchase provides additional information. Insiders have sold a total of 212,904 shares of company stock worth $205,021 in the last quarter. Corporate insiders own 22.04% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. Prudential Financial Inc. acquired a new position in shares of Quantum-Si during the 2nd quarter worth approximately $25,000. Cerity Partners LLC acquired a new position in shares of Quantum-Si during the 2nd quarter worth approximately $29,000. BNP Paribas Financial Markets grew its position in shares of Quantum-Si by 101.3% during the 3rd quarter. BNP Paribas Financial Markets now owns 30,464 shares of the company’s stock worth $43,000 after purchasing an additional 15,331 shares in the last quarter. Dimensional Fund Advisors LP acquired a new position in shares of Quantum-Si during the 4th quarter worth approximately $34,000. Finally, State Board of Administration of Florida Retirement System acquired a new position in shares of Quantum-Si during the 4th quarter worth approximately $45,000. Institutional investors and hedge funds own 39.90% of the company’s stock.

About Quantum-Si

Quantum-Si Inc is a life sciences instrumentation company headquartered in Guilford, Connecticut, developing next-generation proteomics solutions based on semiconductor sequencing technology. The company’s core offering centers on a proprietary single-molecule protein sequencing platform that uses a silicon-based sensor chip to convert protein data into digital signals. This approach is designed to deliver high sensitivity, single-amino-acid resolution and deep proteome coverage while potentially reducing cost and complexity compared to traditional mass spectrometry methods.

Quantum-Si’s product roadmap includes the development and commercialization of an integrated system comprising instruments, consumable reagents and proprietary data analysis software.